The ROC curve showed that ASXL2 expression had a certain power for predicting the 5-year-OS and PAAD patients with high ASXL2 expression tended to exhibit worse clinical outcomes (Figures 1D, E). Here, ASXL2 is linked to pancreatic adenocarcinoma.